ReviewEpilepsy research2015
Current understanding of the mechanism of action of the antiepileptic drug lacosamide.
Review in Epilepsy research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06966830 (A Multicenter, Prospective, Real-World Observational Study of Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus), which is not on this map. Cited by 79 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Prospective, Real-World Observational Study of Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus
Who cites it
79 citing papers in PubMed, 5 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Slow-inactivated sodium channels as a therapeutic target in trigeminal neuralgia: evidence from a systematic review and meta-analysis of lacosamide.Journal of oral & facial pain and headache · 2026Pooled it
- Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis.Frontiers in neurology · 2024Pooled it
- Clinical Efficacy and Safety of Lacosamide as an Adjunctive Treatment in Adults With Refractory Epilepsy.Frontiers in neurology · 2021Pooled it
- Elevated Blood C-Reactive Protein Levels in Patients With Epilepsy: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2019Pooled it
- Dose effects of lacosamide as add-on therapy for partial-onset seizure in adult.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2016Pooled it
- Efficacy and Safety of Adjunctive Cenobamate in Chinese Participants with Focal Seizure.Advances in therapy · 2026Trial
- Distinct impacts of sodium channel blockers on the strength-duration properties of human motor cortex neurons.Epilepsia · 2025Trial
- Trial
- Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open-label, phase 2/3 trial.Epilepsia open · 2023Trial
- Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures.Neurology · 2019Trial
- Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy.Clinical pharmacokinetics · 2017Trial
- Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.Acta neurologica Scandinavica · 2017Trial
- Postoperative Seizure Prophylaxis in Intracranial Tumors: Evaluating the Role of Anti-Seizure Medication in Seizure-Naïve Patients.Current neurology and neuroscience reports · 2026Review
- Article
- Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.Journal of pharmaceutical health care and sciences · 2026Article
- Myocardial Ischemia Associated with Lacosamide Therapy.CJC open · 2026Article
- Review of Physiology, Pathology, and Pharmacology of Voltage-Gated Sodium Channels in Regards to the Potential Role of NaV 1.8 Selective Inhibitor, Suzetrigine, for Chronic Pain Management.Journal of pain research · 2026Review
- Computational drug repositioning approach to predict multi-target therapeutics for epilepsy.Scientific reports · 2025Article
- Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Observational
- Focused ultrasound combined with drug-loaded microbubbles suppresses ictal spikes in kainic acid-induced epileptic animals.Ultrasonics sonochemistry · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The antiepileptic drug lacosamide [(R)-2-acetamido-N-benzyl-3-methoxypropanamide], a chiral functionalized amino acid, was originally identified by virtue of activity in the mouse and rat maximal electroshock (MES) test. Attention was drawn to lacosamide because of its high oral potency and stereoselectivity. Lacosamide is also active in the 6 Hz seizure model but inactive against clonic seizures in rodents induced by subcutaneous pentylenetetrazol, bicuculline and picrotoxin. It is also ineffective in genetic models of absence epilepsy. At doses greater than those required to confer protection in the MES test, lacosamide inhibits behavioral and electrographic seizures in hippocampal kindled rats. It also effectively terminates seizures in the rat perforant path stimulation status epilepticus model when administered early after the onset of seizures. Lacosamide does not exhibit antiepileptogenic effects in kindling or post-status epilepticus models. The profile of lacosamide in animal seizure and epilepsy models is similar to that of sodium channel blocking antiepileptic drugs, such as phenytoin and carbamazepine. However, unlike these agents, lacosamide does not affect sustained repetitive firing (SRF) on a time scale of hundreds of milliseconds or affect fast inactivation of voltage-gated sodium channels; however, it terminates SRF on a time scale of seconds by an apparent effect on sodium channel slow inactivation. Lacosamide shifts the slow inactivation curve to more hyperpolarized potentials and enhances the maximal fraction of channels that are in the slow inactivated state. Currently, lacosamide is the only known antiepileptic drug in clinical practice that exerts its anticonvulsant activity predominantly by selectively enhancing slow sodium channel inactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.